1. Home
  2. JTAI vs INBS Comparison

JTAI vs INBS Comparison

Compare JTAI & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jet.AI Inc.

JTAI

Jet.AI Inc.

HOLD

Current Price

$0.30

Market Cap

4.6M

Sector

Finance

ML Signal

HOLD

INBS

Intelligent Bio Solutions Inc.

HOLD

Current Price

$9.51

Market Cap

5.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JTAI
INBS
Founded
2018
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
5.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
JTAI
INBS
Price
$0.30
$9.51
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$11.00
N/A
AVG Volume (30 Days)
28.7M
7.2M
Earning Date
11-14-2025
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,584,279.00
$3,292,042.00
Revenue This Year
N/A
$778.48
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.26
52 Week Low
$0.26
$4.03
52 Week High
$11.77
$27.50

Technical Indicators

Market Signals
Indicator
JTAI
INBS
Relative Strength Index (RSI) 26.40 48.73
Support Level $0.26 $8.85
Resistance Level $0.43 $24.90
Average True Range (ATR) 0.11 3.50
MACD 0.02 -0.79
Stochastic Oscillator 3.72 7.10

Price Performance

Historical Comparison
JTAI
INBS

About JTAI Jet.AI Inc.

Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.

Share on Social Networks: